NeuroPace has been granted a patent for an implantable medical device that can detect neurological events by analyzing electrical signals from the brain. The device includes electrodes and a waveform analyzer to deliver electrical stimulation therapy in response to detecting epileptiform activity. GlobalData’s report on NeuroPace gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on NeuroPace, Electrical stimulation wearables was a key innovation area identified from patents. NeuroPace's grant share as of May 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Implantable device for detecting neurological events and delivering therapy
A recently granted patent (Publication Number: US11963779B2) discloses an implantable medical device designed for monitoring and detecting epileptiform activity in the brain. The device includes electrodes implanted in the brain and a waveform analyzer that identifies specific electrical signals, determines their characteristics such as amplitude and duration, and analyzes whether they meet predefined criteria for positive or negative slope half waves. If the criteria are met, the waveform is classified as a qualified half wave. By counting the number of qualified half waves within a time window and comparing it to a set criterion, the device can detect electrographic activity indicative of epileptiform activity, triggering the output of electrical stimulation to the electrodes to manage the condition effectively.
Furthermore, the patent also outlines a method for implementing this technology, involving the identification and analysis of half waves in brain signals to determine epileptiform activity. The method includes detailed criteria for assessing the amplitude and duration of half waves, distinguishing between positive and negative slopes, and establishing thresholds for identifying qualified half waves. By monitoring the occurrence of qualified half waves and comparing them to a predefined count criterion, the method enables the detection of epileptiform activity, leading to the delivery of electrical stimulation to the electrodes for therapeutic intervention. This innovative approach offers a promising solution for real-time monitoring and management of epileptic seizures or seizure onsets through precise analysis of brain wave patterns.
To know more about GlobalData’s detailed insights on NeuroPace, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
